The first FDA-approved, DDR-targeted cancer therapeutic drug is olaparib, an inhibitor of poly (ADP-ribose) polymerases (PARP) for the treatment of cancers with inherited BRCA1 or 2 mutations by inducing the synthetic lethality (Lord and Ashworth, 2017). Here, BRCA1 is linked to cancer.